Market Overview

UPDATE: Piper Jaffray Cuts PT to $23 on MAKO Surgical on Volatility

Related MAKO
Credit Suisse Adjusts Estimates and PT on Stryker Following MAKO Acquisition
Benzinga's Top Downgrades

Piper Jaffray reiterated its Overweight rating on MAKO Surgical (NASDAQ: MAKO) and lowered the price target from $28.00 to $23.00.

Piper Jaffray said, “Our revised estimates and price target should position the stock to perform, in the wake of what has been a very volatile 12-month period for MAKO. While our new estimates and target are reduced (robot sales up 14%, implant sales up 40%, total revenues up 30%, $23 down from $28), the numbers strike a compelling growth profile by any standard and we believe there remains potential for upside revisions. MAKO clearly remains a “show-me” stock, and management must position 2013 outlook balancing growth and conservatism, and importantly, meeting or beating numbers for a quarter or two.”

MAKO Surgical closed at $12.22 on Friday.

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (MAKO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters